Tapinarof cream 1% once daily for the treatment of plaque psoriasis: Patient-reported outcomes from the PSOARING 3 trial
Authors:
Open Access
- 10 May 2023
- journal article
- research article
- Published by Elsevier in Journal of the American Academy of Dermatology
- Vol. 89 (5) , 936-944
Abstract
No abstract availableKeywords
This publication has 32 references indexed in Scilit:
- A systematic review of the use of quality-of-life instruments in randomized controlled trials for psoriasisBritish Journal of Dermatology, 2016
- US Perspectives in the Management of Psoriasis and Psoriatic Arthritis: Patient and Physician Results from the Population-Based Multinational Assessment of Psoriasis and Psoriatic Arthritis (MAPP) SurveyAmerican Journal of Clinical Dermatology, 2015
- Undertreatment, Treatment Trends, and Treatment Dissatisfaction Among Patients With Psoriasis and Psoriatic Arthritis in the United StatesJAMA Dermatology, 2013
- Reporting of Patient-Reported Outcomes in Randomized TrialsJAMA, 2013
- Definition of treatment goals for moderate to severe psoriasis: a European consensusArchives of Dermatological Research, 2010
- Development and Validation of the “Treatment Satisfaction with Medicines Questionnaire” (SATMED-Q)©Value in Health, 2008
- How patients experience psoriasis: results from a European surveyJournal of the European Academy of Dermatology and Venereology, 2005
- Translating the Science of Quality of Life into Practice: What Do Dermatology Life Quality Index Scores Mean?Journal of Investigative Dermatology, 2005
- Validation of a general measure of treatment satisfaction, the Treatment Satisfaction Questionnaire for Medication (TSQM), using a national panel study of chronic diseaseHealth and Quality of Life Outcomes, 2004
- Dermatology Life Quality Index (DLQI)-a simple practical measure for routine clinical useClinical and Experimental Dermatology, 1994